The FDA has approved a label expansion for the interleukin-23 inhibitor guselkumab to include the inhibition of structural joint damage progression in adults with psoriatic arthritis.

The Medical News Today news team reports on emerging science, cutting-edge research, new treatments, and trending topics in health and medicine. All articles are written by our network of editors and ...